OncoSec Medical Incorporated (ONCS) financial statements (2023 and earlier)

Company profile

Business Address 24 N. MAIN STREET
PENNINGTON, NJ 08534
State of Incorp. NV
Fiscal Year End July 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

1/31/2022
TTM
7/31/2021
7/31/2020
7/31/2019
7/31/2018
7/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments25,23145,95120,35425,1483,80411,445
Cash and cash equivalents25,23145,95120,35425,1483,80411,445
Prepaid expense    1,6441,069
Other undisclosed current assets2,6973,2282,4673,36023,174 
Total current assets:27,92849,17922,82228,50728,62212,514
Noncurrent Assets
Operating lease, right-of-use asset5,1495,4465,948 
Property, plant and equipment1,0719298141,0311,2662,410
Intangible assets, net (including goodwill)413448    
Intangible assets, net (excluding goodwill)413448    
Other noncurrent assets528274319354359309
Total noncurrent assets:7,1617,0977,0821,3851,6252,719
TOTAL ASSETS:35,08956,27629,90329,89230,24615,233
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3,4545,5627,9234,2174,7793,281
Accrued liabilities5833212856761,0711,585
Employee-related liabilities583321285  115
Other undisclosed accounts payable and accrued liabilities2,2894,9207,3533,5413,7081,581
Debt4971,23497084  
Other undisclosed current liabilities1,6201,1667856761,071115
Total current liabilities:5,5727,9629,6784,9775,8503,396
Noncurrent Liabilities
Long-term debt and lease obligation4,7035,2386,355   
Long-term debt, excluding current maturities  481   
Operating lease, liability4,7035,2385,874 
Liabilities, other than long-term debt   6361,4731,141
Other liabilities   6361,4731,141
Other undisclosed noncurrent liabilities297(238)(5,874)   
Total noncurrent liabilities:9,70310,2386,3556361,4731,141
Total liabilities:15,27418,20016,0335,6137,3224,537
Stockholders' equity
Stockholders' equity attributable to parent19,81538,07613,87024,27922,92410,696
Common stock442152
Additional paid in capital287,540286,337214,790177,656145,74493,866
Accumulated other comprehensive income (loss)174(79)(20)169(16)(4)
Accumulated deficit(271,494)(251,778)(206,610)(164,357)(134,081)(94,944)
Warrants and rights outstanding3,5923,5925,70810,81011,27111,776
Total stockholders' equity:19,81538,07613,87024,27922,92410,696
TOTAL LIABILITIES AND EQUITY:35,08956,27629,90329,89230,24615,233

Income statement (P&L) ($ in thousands)

1/31/2022
TTM
7/31/2021
7/31/2020
7/31/2019
7/31/2018
7/31/2017
Operating expenses(43,646)(48,380)(43,409)(30,417)(36,105)(21,448)
Operating loss:(43,646)(48,380)(43,409)(30,417)(36,105)(21,448)
Nonoperating income (expense)(663)(145)185440310 
Foreign currency transaction gain (loss), before tax(659)(144)103(281)  
Interest and debt expense942945(5)(4)  
Loss from continuing operations before equity method investments, income taxes:(43,367)(47,580)(43,229)(29,980)(35,795)(21,448)
Other undisclosed income (loss) from continuing operations before income taxes  103(294)(3,340) 
Loss from continuing operations before income taxes:(43,367)(47,580)(43,126)(30,275)(39,136)(21,448)
Income tax expense (benefit)2,4122,412873(1)(1)(1)
Net loss attributable to parent:(40,954)(45,168)(42,253)(30,276)(39,136)(21,450)
Other undisclosed net loss available to common stockholders, basic    (94,964) 
Net loss available to common stockholders, diluted:(40,954)(45,168)(42,253)(30,276)(134,100)(21,450)

Comprehensive Income ($ in thousands)

1/31/2022
TTM
7/31/2021
7/31/2020
7/31/2019
7/31/2018
7/31/2017
Net loss:(40,954)(45,168)(42,253)(30,276)(39,136)(21,450)
Other comprehensive income (loss)206(60)(189)18539,14921,453
Comprehensive income (loss):(40,748)(45,227)(42,442)(30,091)124
Other undisclosed comprehensive income (loss), net of tax, attributable to parent253   (39,161) 
Comprehensive income (loss), net of tax, attributable to parent:(40,495)(45,227)(42,442)(30,091)(39,149)4

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: